RSV — Total Revenue
Moderna RSV — Total Revenue increased by 75.0% to $7.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 250.0%, from $2.00M to $7.00M. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase indicates successful product launch, market penetration, and growing demand for the vaccine, while a decrease may signal competitive pressure or lower-than-expected immunization rates.
Detailed definition
This metric represents the total gross revenue generated from the sale of respiratory syncytial virus (RSV) vaccine prod...
Peer comparison
Comparable to vaccine or therapeutic segment revenues at other large-cap biopharmaceutical companies, often benchmarked against seasonal demand cycles and market share in the infectious disease space.
mrna_segment_rsv_total_revenueHistorical Data
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $10.00M | $15.00M | $2.00M | $0.00 | $2.00M | $4.00M | $7.00M |
| QoQ Change | — | — | — | — | — | — | — | — | — | +50.0% | -86.7% | -100.0% | — | +100.0% | +75.0% |
| YoY Change | — | — | — | — | — | — | — | — | — | — | — | — | -80.0% | -73.3% | +250.0% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Moderna's rsv — total revenue?
- Moderna (MRNA) reported rsv — total revenue of $7.00M in Q1 2026.
- How has Moderna's rsv — total revenue changed year-over-year?
- Moderna's rsv — total revenue increased by 250.0% year-over-year, from $2.00M to $7.00M.
- What does rsv — total revenue mean?
- The total sales revenue generated from the company's respiratory syncytial virus vaccine product line.